Original Article

Eliminating Disparities in Hypertension Care for Hispanics and Blacks Using a Heart Failure Disease Management Program

Authors: Kathy Hebert, MD, MMM, MPH, Elyse Julian, BS, Jorge Alvarez, MD, PhD, Andre Dias, MD, Leonardo Tamariz, MD, MPH, Lee Arcement, MD, MPH, Henry C. Quevedo, MD

Abstract

Objectives: This study assessed if patients enrolled in a heart failure disease management program (HFDMP) reach the JNC VII target goals for blood pressure (BP) control, eliminate disparities in hypertension control by race/ ethnicity and the impact BP control has on survival.


Methods: Patients (N = 898) with an ejection fraction <40% were enrolled into two HFDMPs and screened for hypertension, defined as BP > 130/80.


Results: Mean baseline systolic BP (SBP) 132 ± 25.5 mm Hg and diastolic BP (DBP) 79 ± 16.8 mm Hg. Final mean SBP decreased to 129.6 mm Hg, DBP 77.6 mm Hg. Whites had the highest rate of achieving BP goals. Mortality reduction was associated with minority race, history of hypertension, increase ejection fraction and statin use.


Conclusion: HFDMPs are an effective way to reduce BP in hypertensive patients. Disparities by race and ethnicity were not seen after adjustment for disease modifiers. There was no mortality difference in those who reached BP goal.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404.
 
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2572.
 
3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-313.
 
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
 
5. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-3072.
 
6. American Heart Association. Heart Disease & Statistics: 2009 Update At-a-Glance. Circulation 2009;119:480-486.
 
7. Todd WE, Nash DB. Disease Management: A Systems Approach to Improving Patient Outcomes. New York: John Wiley & Sons, 2001.
 
8. Bernard DB, Townsend RR, Sylvestri MF. Health and disease management: what is it and where is it going? What is the role of health and disease management in hypertension? Am J Hypertens 1998;11(8 Pt 2):103S-108S; discussion 109S-111S.
 
9. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-2788.
 
10. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-e194.
 
11. Ara S. A literature review of cardiovascular disease management programs in managed care populations. J Manag Care Pharm 2004;10:326-344.
 
12. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005;111:697-716.
 
13. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
 
14. Gourley GA, Portner TS, Gourley DR, et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash) 1998;38:586-597.
 
15. Bogden PE, Abbott RD, Williamson P, et al. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13:740-745.
 
16. Hetlevik I, Holmen J, Kruger O. Implementing clinical guidelines in the treatment of hypertension in general practice. Evaluation of patient outcome related to implementation of a computer-based clinical decision support system. Scand Prim Health Care 1999;17:35-40.
 
17. Fielding JE, Knight K, Mason T, et al. Evaluation of the IMPACT blood pressure program. J Occup Med 1994;36:743-746.
 
18. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17:140-147.
 
19. Montgomery AA, Fahey T, Peters TJ, et al. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000;320:686-690.
 
20. Giles T, Aranda JM Jr, Suh DC, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich) 2007;9:345-354.
 
21. Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007;55:1056-1065.
 
22. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26-32.
 
23. Poon I, Lal LS, Ford ME, et al. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother 2009;43:185-193.
 
24. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J 2005;41:521-537.
 
25. Gellad WF, Haas JS, Safran DG. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med 2007;22:1572-1578.
 
26. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009;CD004349.
 
27. Phend C. Lower blood pressure targets offer no benefits. http://www.medpagetoday.com/Nephrology/Hypertension/15003. Published July 8, 2009. Accessed June 26, 2011.